A look at the clinical features that predict for early discontinuation with checkpoint blockade in ovarian cancer
Reader Q&A on women's cancers relating to HER2, PARP and TNBC...
Latest BSB reader Q&A looks at 5 questions from subscribers
The third PARP inhibitor in ovarian cancer hits the market - what's the latest story?
What can we learn from the early data exploring PARPi plus checkpoint blockade combinations in ovarian cancer?